Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


MHLW (Japan) approves Jardiance (empagliflozin) for the treatment of chronic kidney disease (CKD) – Nippon Boehringer Ingelheim

Written by | 26 Feb 2024

MHLW (Japan) approved on February 9 Nippon Boehringer Ingelheim’s SGLT2 inhibitor Jardiance (empagliflozin) for the treatment of chronic kidney disease (CKD) </p. Jardiance has been available in Japan… read more.

New drug could prevent diabetic eye and kidney disease in people with diabetes

Written by | 16 Feb 2024

New research has shown a new type of inhibitor drug could prevent microvascular diabetic complications, such as diabetic eye and kidney disease.  The University of Bristol-led research is… read more.

MHLW (Japan) orders label revisions to five anticoagulants to advise the risk of kidney injury

Written by | 30 Nov 2023

The Ministry of Health, Labor and Welfare (MHLW) on November 21 ordered label revisions for five anticoagulants to newly advise the risk of acute kidney injury, including Bristol… read more.

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study in kidney transplant patients – Hansa Biopharma

Written by | 20 Oct 2023

Hansa Biopharma announced results from an extended pooled analysis using data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant… read more.

Update on ConfIdeS phase III trial of imlifidase in highly sensitized kidney transplant patients – Hansa Biopharma

Written by | 17 Oct 2023

Hansa Biopharma announced randomization for the US ConfIdeS trial is expected to conclude in mid-2024. The ConfIdeS trial is an open-label, controlled, randomized Phase III trial evaluating 12-month… read more.

FDA approves Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease – Boehringer + Eli Lilly

Written by | 28 Sep 2023

Boehringer Ingelheim and Eli Lilly and Company announced that the FDA has approved Jardiance (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular… read more.

New kidney function equation may reduce health disparities by improving access to heart failure therapy in previously ineligible patients

Written by | 18 Aug 2023

Physician-scientists from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine recently conducted a large-scale analysis to assess the impact of a newly introduced equation used to evaluate… read more.

Consuming added sugars may increase risk of kidney stones

Written by | 10 Aug 2023

Between 7% and 15% of people in North America, between 5% and 9% of people in Europe, and between 1% and 5% of people in Asia suffer from… read more.

Patient-led intervention first to successfully address multiple difficult symptoms in dialysis patients

Written by | 17 Jul 2023

When a patient with chronic kidney disease finally reaches the point that their kidneys fail, doctors have a treatment available: dialysis. But undergoing dialysis often brings a high burden of other… read more.

Even a modest reduction in kidney function increases health risks in young adults

Written by | 27 Jun 2023

A study of more than 8 million adults in Ontario, Canada suggests that even a modest loss of kidney function is associated with increased health risks. The study,… read more.

Treating asymptomatic elevated blood pressure linked to cardiac and kidney injury

Written by | 4 Jun 2023

Blood pressure is closely monitored in hospitalized patients. Severely high blood pressure can lead to a heart attack, stroke, or damage blood vessels and organs including the heart,… read more.

Study finds certain substances in urine, blood can predict kidney disease progression

Written by | 7 Apr 2023

In a new study looking at the long-term effects of hospitalized patients who have acute kidney injury (AKI), a sudden but temporary loss of kidney function, Johns Hopkins… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.